Abstract
High Prevalence of Hyperuricemia and Gout in North American Patients with IgA Nephropathy
Highlights
The relationship between hyperuricemia (HU) and chronic kidney disease (CKD) has been a topic of great interest in recent years [1,2,3,4] and some studies have shown that lowering serum uric acid (SUA) levels may slow the rate of progression of CKD [5,6]
We report SUA levels in 153 IgA nephropathy (IgAN) patients aged ≥ 20 years of age from Canada and the United States (USA) who were enrolled in two multicenter trials [30,31]
The prevalence of HU in the 145 nongout IgAN patients aged 20-59 years is compared with the general US population in Table 1 [34]
Summary
The relationship between hyperuricemia (HU) and chronic kidney disease (CKD) has been a topic of great interest in recent years [1,2,3,4] and some studies have shown that lowering serum uric acid (SUA) levels may slow the rate of progression of CKD [5,6]. Reports describing HU in adult patients with IgA nephropathy (IgAN) have been especially prominent [7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25] and have increased rapidly since 2010 [14,15,16,17,18,19,20,21,22,23,24,25]. We report SUA levels in 153 IgAN patients aged ≥ 20 years of age from Canada and the United States (USA) who were enrolled in two multicenter trials [30,31]. We define the correlation between SUA and CKD categories, as determined by two formulas [32,33] in non-gout IgAN patients, and describe the features of 7 gout patients within this cohort
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
